Effice Servicios Para la Investigacion S.L.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Madrid Spain (2004)

Organization Overview

First Clinical Trial
2012
NCT01820078
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Effice Servicios Para la Investigacion S.L.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 4)

Coronavirus Infections (Phase 3)

Crohn Disease (Phase 3)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Infections (Phase 3)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Neoplasm Metastasis (Phase 4)

Recurrence (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 9